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Background: New tuberculosis (TB) vaccines are being developed to combat the global epidemic. A phase
IIb trial of a candidate vaccine, MVA85A, was conducted in a high burden setting in South Africa to
evaluate proof-of-concept efﬁcacy for prevention of TB in infants.
Objective: To describe the study design and implementation lessons from an infant TB vaccine efﬁcacy
trial.
Methods: This was a randomised, controlled, double-blind clinical trial comparing the safety and efﬁcacy
of MVA85A to Candin control administered to 4e6-month-old, BCG-vaccinated, HIV-negative infants at
a rural site in South Africa. Infants were followed up for 15e39 months for incident TB disease based on
pre-speciﬁed endpoints.
Results: 2797 infants were enrolled over 22 months. Factors adversely affecting recruitment and the
solutions that were implemented are discussed. Slow case accrual led to six months extension of trial
follow up.
Conclusion: The clinical, regulatory and research environment for modern efﬁcacy trials of new TB
vaccines are substantially different to that when BCG vaccine was ﬁrst evaluated in infants. Future infant
TB vaccine trials will need to allocate sufﬁcient resources and optimise operational efﬁciency. A stringent
TB case deﬁnition is necessary to maximize speciﬁcity, and TB case accrual must be monitored closely.
 2013 Elsevier Ltd.Open access under CC BY license.1. Background
Nine million new cases of tuberculosis (TB) occur worldwide
each year and it is estimated that 1 million (11%) are in children: þ27 23 346 5406.
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 license.under 15 years.1 Universal infant vaccination with Mycobacterium
bovis bacille Calmette-Guérin (BCG), the only licensed TB vaccine, is
routine in TB endemic settings.2 BCG vaccination coverage is
greater than 95% in South Africa3 where TB incidence is 981/
100,000.4 BCG vaccination confers consistent, but partial protection
against disseminated forms of TB2,5 but protection against pulmo-
nary disease in children and adults is highly variable.6 A more
effective TB vaccine is needed urgently.
Over ten candidate TB vaccines designed either to boost BCG or
replace it are at different stages of clinical testing.7 One of these
novel vaccines, MVA85A, is a recombinant strain of Modiﬁed
Vaccinia virus Ankara expressing the Mycobacterium tuberculosis
(Mtb) antigen 85A (Ag85A)8 and is designed to boost the immune
response to BCG. The safety and immunogenicity of MVA85A have
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children, and infants.9e19
The TB vaccine trial landscape has changed markedly in the half
century since the infant BCG efﬁcacy trials of Rosenthal and
Aronson.20,21 Modern clinical trials are conducted in a highly
regulated research environment, inwhich the safety of participants
is paramount, guided by the principles of International Conference
on Harmonisation Good Clinical Practice (ICH-GCP). The intro-
duction of effective anti-tuberculous chemotherapy for TB disease
and isoniazid preventive therapy (IPT) for TB-exposed children,
coupled with the need for active surveillance for early detection
and treatment, has dramatically shifted the TB phenotype observed
in modern vaccine trials towards an early, mild presentation.22e24
These considerations impact negatively on the diagnosis of child-
hood TB as the efﬁcacy endpoint of such trials, even in high TB
burden countries, which have traditionally reported cases of
advanced childhood TB disease.23,25 Further, vaccine-induced pro-
tection by any new TB vaccine must be demonstrated in addition to
that conferred by BCG. It follows that case-ﬁnding strategies and
deﬁnition of TB disease endpoints will be crucial to the successful
demonstration of efﬁcacy of any new infant TB vaccine.
A phase IIb proof-of-concept safety and efﬁcacy trial of an infant
BCG e prime and MVA85A e boost regimen began enrolment in
July 2009, at the ﬁeld site of the South African Tuberculosis Vaccine
Initiative (SATVI) near Cape Town. This is the ﬁrst infant efﬁcacy
trial of a new TB vaccine to be conducted since BCG. We report on
the operational and scientiﬁc challenges experienced by the study
team during the conduct of this trial.
2. Methods
2.1. Study design
This was a parallel randomized, controlled, double-blind clinical
trial with a 1:1 ratio of intervention to control.
2.2. Study population
The SATVI ﬁeld site is set in a region where the TB incidence
across all ages is 1400/100,000 and the incidence in children
younger than two years of age is estimated at 1500/100,000.26e28
The study area has a total population of 350,000 with an annual
birth cohort of 7000. Healthy BCG-vaccinated infants aged 4e6
months, without evidence of individual or maternal HIV infection,
without evidence of TB exposure or infection, and whose routine
immunizations were up to date, were enrolled.
2.3. Recruitment, consenting and screening
Mothers of infants of 6 weeks or older were approached for
possible participation in the trial. Once informed consent had been
signed by the legal guardian, the infants were randomised
sequentially into one of ﬁve cohorts starting with an initial safety
cohort of at least 330 participants, followed by three immunoge-
nicity cohorts of up to 60 participants each and the ﬁnal, largest
correlates of protection cohort of 2400.
2.4. Inclusion/Exclusion criteria at commencement of trial
Infants were required to be between 126 and 154 days old at
randomisation, to have received BCG vaccination within 7 days of
birth, to have received routine doses of EPI vaccines, including
pneumococcal vaccine more than 28 days prior to randomisation,
and have a weight >10th percentile at randomisation. Infants were
excluded if they had an acute illness or fever 37.5 C on Day 0,evidence of infant or maternal HIV infection, evidence of chronic
hepatitis, a positive QuantiFERON TB Gold (in-tube) test (QFT)
(Cellestis, Victoria, Australia) or a history of known TB disease,
treatment of TB, or household TB contact.
2.5. Randomization and blinding
Infants conﬁrmed eligible were randomized to receive 0.06 mL
of either MVA85A vaccine candidate (1  108 plaque forming units
[pfu]) or Candida skin test antigen control, Candin, by intradermal
injection into the left deltoid region using amasked labeled syringe.
Candinwas selected for its intradermal administrationwith similar
local reactogenicity to MVA85A, thus ensuring unbiased safety and
efﬁcacy assessments. The study pharmacist was the only member
of the ﬁeld team unblinded to allocation of the investigational
product. The infants’ caregivers and study staff involved in all other
aspects of the trial remained blinded to treatment allocation
throughout the trial.
2.6. Outcomes
The primary objective of this study was to evaluate the safety
proﬁle of MVA85A in BCG-vaccinated, HIV-negative infants. The
secondary objectives were: 1) to evaluate the efﬁcacy of the
MVA85A vaccine compared to placebo control in the prevention of
TB disease using three clinical endpoints, 2) the evaluation of the
immunogenicity of MVA85A compared to controls and 3) the
evaluation of the rate ofMtb infection, as deﬁned by QFTconversion
at ﬁnal study assessment in MVA85A recipients compared to con-
trols in infants without a diagnosis of TB disease during the trial.
2.7. Follow up
All enrolled infants were followed for efﬁcacy. Infants were to be
followed up for between 9 months and 33 months (mean 18
months) by visits to the trial clinic and home visits. Legal guardians
were interviewed about the health status of the participant with
a focus on possible TB symptoms, and phlebotomy was done per
protocol for safety and immunogenicity assessments. Blood was
drawn for QFT at Day 336 and at the end of study visit.
2.8. Safety endpoints
Adverseevents, both local andsystemic,were recorded for theﬁrst
twenty-eight days post-vaccination, and classiﬁed for severity and
relationship to vaccine. Serious adverse events (SAEs) were collected
for thedurationof studyparticipation throughactive surveillance and
self-reporting at routine visits. SAEs were reported within speciﬁed
time frames to the sponsor, regulatory authorities and the ethics
committee. An unblinded safety review by the Safety andMonitoring
Committee occurred after completion of Day 28 for the initial safety
cohort and again after Day 84 for the 1000th participant.
2.9. Case accrual and efﬁcacy endpoints
Follow-up visits and active surveillance of hospital records, clinic
TB registers, radiology records and death certiﬁcates were used to
identify suspected cases of TB. A household TB contact would also
trigger a case-ﬁnding process.28 Any infant suspected of TB, or with
a history of TB contact, or known tuberculin skin test (TST) or QFT
conversion, was admitted to a case veriﬁcation ward (CV ward) for
standardized investigations.26,28 Children who were diagnosed as
having TBandstartedon treatment by thehealth serviceswerewhere
possible admitted to the CV ward as soon as possible after diagnosis
for these investigations. A trial-independent, hospital-based TB
Table 1
Endpoint deﬁnitions.
TB case deﬁnition Endpoint #1
Any of the following numerical categories
 Isolation of M. tuberculosis from any site.
 Identiﬁcation of M. tuberculosis by an approved molecular diagnostic
technique from any site.
 Histopathology diagnostic for tuberculosis disease (such as caseating
granulomas)
 Choroidal tubercle diagnosed by an ophthalmologist
 Miliary pattern on chest X-ray in an HIV-negative infant
 Clinical diagnosis of tuberculous meningitis (CSF protein >0.6 g/L
and pleocytosis >50/mm3 with mononuclear cell >50%) with features
of basal meningeal enhancement and hydrocephalus on head CT.
 Vertebral spondylosis
 A single smear/histology specimen positive for acid fast (or auramine
positive) bacilli from a normally sterile body site.
 One of the following:
a) Two acid fast or auramine smears positive each from a separate
collection morphologically consistent with mycobacteria from
either sputum or gastric aspirate that are not found to be non-
tuberculous mycobacteria bacteria on culture, OR
b) QuantiFERON conversion from negative or indeterminate to
positive, OR
c) Tuberculin skin test 15 mm
AND
One of the following compatible radiographic features:
a) Calciﬁed Ghon focus, OR
b) Pulmonary cavity, OR
c) Hilar/mediastinal adenopathy, OR
d) Pleural effusion, OR
e) Airspace opaciﬁcation,
ANDOne of the following clinical manifestations:
a) Cough without improvement for longer than two weeks, OR
b) Weight loss of at least 10% of body weight for at least 2 months, OR
c) Failure to thrive (crossing at least one entire major centile band
downward) for at least 2 months, where the major centile bands are
deﬁned as <97the90th, <90the75th, <75the50th, <50the25th,
<25the10th, and <10the3rd weight-for-age centiles.*
TB case deﬁnition Endpoint #2
Any of the following numerical categories
 Isolation of M. tuberculosis from any site.
 Identiﬁcation of M. tuberculosis by an approved molecular diagnostic
technique from any site.
 Histopathology diagnostic for tuberculosis disease (such as caseating
granulomas)
 Choroidal tubercle diagnosed by an ophthalmologist.
 Miliary pattern on chest X ray in an HIV-negative infant
 Clinical diagnosis of tuberculous meningitis (CSF protein >0.6 g/L and
pleocytosis >50/mm3 with mononuclear cell >50%) or features of basal
meningeal enhancement and hydrocephalus on head CT.
 Vertebral spondylosis
 A single smear/histology specimen positive for acid fast (or auramine
positive) bacilli from a normally sterile body site.
 One of the following:
a) One acid fast or auramine smear positive morphologically
consistent with mycobacteria from either sputum or gastric aspirate
that are not found to be non-tuberculous mycobacteria bacteria on
culture, OR
b) QuantiFERON conversion from negative or indeterminate to
positive, OR
c) Residence in a household with an AFB smear positive member, OR
d) Tuberculin skin test 10 mm
AND
One of the following compatible radiographic features:
a) calciﬁed Ghon focus, OR
b) pulmonary cavity, OR
Table 1 (continued )
TB case deﬁnition Endpoint #2
c) hilar/mediastinal adenopathy, OR
d) pleural effusion, OR
e) airspace opaciﬁcation, OR
AND One of the following clinical manifestations:
a) Cough without improvement for longer than two weeks, OR
b) Weight loss of at least 10% of body weight for at least 2 months, OR
c) Failure to thrive (crossing at least one entire major centile band
downward) for at least 2 months, where the major centile bands are
deﬁned as <97the90th, <90the75th, <75the50th, <50the25th,
<25the10th, and <10the3rd weight-for-age centiles.*
TB case deﬁnition Endpoint #3
All individuals who are placed on anti-tuberculosis therapy with the intent of
treating tuberculosis regardless of whether they have met the other efﬁcacy
endpoints
* Centers for Disease Control (CDC) Growth Charts (USA), developed by the Na-
tional Center for Health Statistics in collaboration with the National Center for
Chronic Disease Prevention and Health Promotion (2000).
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appropriate care and treatment. Digital chest X-ray images were
reviewed by an independent, blinded panel of three expert paediatric
radiologists. A majority agreement on the presence of pre-speciﬁed
radiological pathology was required for a chest X-ray to be classi-
ﬁed as positive for inclusion in the primary efﬁcacy endpoint. The
endpoint deﬁnitions used to deﬁne a TB case are set out in Table 1.
2.10. Sample size determination
Given estimated tuberculosis cumulative incidence of 3% over 18
months in the control group, 1392 subjects per study group would
provide a 90% chance of detecting a 60% reduction between the
treated and control groups based on a two-sided log rank test at
a signiﬁcance level of 0.05. The enrolment target for the study was
thus 2784 infants. A sample size of 1392MVA85Avaccinated subjects
would give a greater than 75% chance of observing an adverse event
that has an approximately 1 in a 1000 actual rate of occurrence.
2.11. Study approvals
The trial was approved by the University of Cape Town (UCT)
Faculty of Health Sciences Human Research Ethics Committee
(REC), Oxford University Tropical Research Ethics Committee and
the South AfricanMedicines Control Council (MCC). Permissionwas
obtained from the Western Cape Department of Health to access
their health facilities.
2.12. Clinical trials registration
The trial was registered on South African National Clinical Trials
Register in November 2008 (DOH-27-0109-2654) and on
clinicaltrials.gov in July 2009 (NCT00953927).
3. Results
Enrolment commenced in July 2009 and was completed in May
2011. 4754 parents/legal guardians signed consent and 2797 infants
were successfully screened and enrolled. The main reasons for
exclusion are set out in Figure 1.Slightly more infants were enrolled
than targeted because all infants that had already entered screen-
ing were allowed to be enrolled although the enrolment target of
2784 had been reached. Closeout visits were completed in
Figure 1. Main reasons for screening failure.
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closeout visits continued until October 2012.
Challenges arising from study design elements, operational
lessons from implementation of the protocol, and alternative ap-
proaches and solutions are summarised in Table 2.
3.1. Recruitment
3.1.1. Site of recruitment
Previous experience at our site had taught us to expect an initial
slow pace for screening and enrolment before gaining momentum,
exhibiting an S-shaped enrolment rate curve.29 However, the initial
pace was even slower than expected forcing a review of our
recruitment methods. The initial recruitment plan was to approach
mothers of infants attending public health clinics for the routine
6-week vaccination visit. This strategy failed due to limited space
for study staff in the clinics and a reluctance of mothers to lengthen
their clinic stay by engaging with our staff. A protocol amendment
allowed us access to home addresses in the birth registers and
vaccination records at local public health facilities which enabled
our staff to visit parents at home resulting in substantially more
effective recruitment.
3.1.2. Stafﬁng
Initial planning underestimated the number of staff needed to
cope with the large numbers to be recruited and vast distances to be
travelled. The study area is approximately 10,000 km2 and included
the inhabitants of ﬁfteen towns and hundreds of surrounding farms.Table 2
Study design and operational factors, implementation lessons learned, and alternative a
Category Design/Operational factor
Recruitment Site of recruitment
Sub-optimal ﬁeld staff allocation
Informed consent
Screening procedures and application
of inclusion/exclusion criteria
Community attitudes to phlebot
Specimen haemolysis
Deﬁnition of TB exposure
Thrombocytosis e inappropriate
laboratory reference ranges
Impact of routine immunisation
Case accrual TB case accrualWe increased staff as follows: four additional ﬁeld workers for
recruitment (initially n ¼ 28) and ten more research nurses (initially
n ¼ 6) for screening, vaccination, follow-up activities and safety as-
sessments. In addition, we assigned staff to purely administrative
duties and re-organised the study staff into teamswith team leaders.
This had a positive impact on recruitment.
3.1.3. Informed consent
As professional nurses are a scarce resource needed for clinical
tasks, we invited GCP-trained lay ﬁeldworkers to undergo training in
the informed consent process. Competence was evaluated through
role-play and successful candidates were accredited to conduct
informed consent. This increased the pool of staff available to con-
duct informed consent which led to an increase in enrolment rates.3.2. Screening procedures and application of inclusion/exclusion
criteria
3.2.1. Phlebotomy technique
Approximately 3% of parents/caregivers who consented to par-
ticipate in the trial withdrew during the screening phase, for a va-
riety of reasons. About 20% of those who gave a reason said they
were distressed by the phlebotomy process. Study nurses received
additional training in infant phlebotomy from a paediatrician, who
emphasised the use of appropriate anatomical sites (cubital fossa,
hand or foot before external jugular vein), swaddling and the use of
sucrose solution as an analgesic.30,31 A limit of maximum three
phlebotomy attempts was set and the need to explain the proce-
dure to the mother or caregiver was emphasised.
3.2.2. Haemolysis of blood specimens
Haemolysed safety blood samples could not be processed by the
laboratory necessitating repeated phlebotomy. This was not always
well received by participant’s parents, placed an increased burden on
the screening clinic numbers and had budgetary implications. We
introduced centrifugation of all blood samples for biochemistry
testing at 3750 rpm for 10 min at the trial site laboratory before
transport and delivery of samples to the diagnostic laboratory 110 km
away and this substantially reduced the rate of haemolysed samples.
3.2.3. TB exposure
We found that staff in ﬁrst contact with potential participants
was over-interpreting the exclusion criterion related to household
TB contact. A clear deﬁnition of the term “household TB contact”
was developed by the study medical team which deﬁned a house-
hold contact as follows: one who has been diagnosed with TB after
the infant’s birth, and spent more than 6 h daily in the same living
space. If the household member has been diagnosed with pulmo-
nary TB before the infant’s birth, they would qualify as a householdpproaches and solutions.
Alternative/Solution
Ensure conducive environment for informed consent
Ensure adequate staff allocation
Train lay ﬁeld workers in informed consent
omy Ensure correct paediatric phlebotomy technique and counsel
parents about procedure.
Centrifugation of specimens prior to transport
Clear detailed deﬁnition e investigator assessment required
Inclusion based on investigator clinical assessment
s Widen vaccination window, be prepared for stockouts and
mass immunisations campaigns
Monitor case accrual and extend follow up if needed.
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or was a treatment defaulter or had drug resistant TB. The decision
to exclude an infant based on “household TB contact” was made
only by an investigator.
3.2.4. Thrombocytosis
Screening haematology tests revealed a high prevalence of
thrombocytosis in otherwise healthy infants. More than 90% of in-
fants screened had platelet counts above the local laboratory deﬁned
upper limit of normal (350  109/L) with 51% of screening values
greater than 500  109/L. These reference ranges are derived from
Western sources and not local data. Based on a haematologist’s
advice to interpret the results in a clinical context, we enrolled in-
fants with thrombocytosis providing other haematological parame-
ters were within the normal range and the infant was clinically well.
3.2.5. Impact of routine immunisations
We found that the 14-week routine immunisation doses were
often delayed, resulting in study exclusions when the 28 day win-
dow between the receipt of routine immunisations and admin-
istration of the study vaccine fell after the 154 day age cut-off for
study vaccination. A protocol amendment was approved to reduce
the window between routine vaccines and the investigational
vaccine to 14 days and to increase the age of eligibility for vacci-
nation to 26 weeks. This reduced exclusion of infants due to being
out of the vaccination window.
A temporary global shortage of BCG threatened enrolment, as
eligibility for participation required receipt of BCG within seven days
of birth. The local Department of Health arranged for areas with
excess stock to share this with the birthing units in our study
drainage area and arranged for the ﬁrst new batch of BCG stock to be
distributed in our study area tominimise the impact of this shortage.
A national polio eradication campaign, targeting all children
from birth to 5 years regardless of immunisation status also
threatened to disrupt enrolment. The campaign involved the
administration of two doses of trivalent oral polio, four weeks
apart. An arrangement was reached with the local health author-
ities whereby administration of polio vaccine was delayed until
after study vaccine administration.
3.3. Case accrual
3.3.1. Efﬁcacy follow up
Blinded case accrual was monitored throughout study follow up.
About nine months prior to study closeout, it was determined that
insufﬁcient TB cases would be accrued by study end to ensure statis-
tical signiﬁcance for the efﬁcacy objective. Twenty-one casesmeeting
theendpoint 1deﬁnitionhadbeen accrued at thatpoint,when33e35
had been expected. An amendment to lengthen follow up by six
months was submitted and approved to address this shortfall.
4. Discussion
Designing and operationalising this ﬁrst efﬁcacy trial of a TB
vaccine candidate in infants was complicated by the lack of a single
test to diagnose childhood TB. This necessitated a clear clinical
endpoint deﬁnition, a lengthy follow-up period and a large sample
size. In modern times, regulatory authorities and ethics commit-
tees, and investigators and sponsors are much more sensitised to
participant rights particularly in trials conducted in vulnerable
populations. We used the experience gained from the conduct of
a large BCG trial26 and a neonatal cohort study of TB in28 infants to
design and plan for this clinical trial. In practice, there was an
evolutionary process with respect to study design and operational
activities as the trial progressed.4.1. Study design
A standard vaccine efﬁcacy trial design has been described. An
area warranting further discussion is the clinical endpoint selec-
tion. The diagnosis of TB in children is challenging as the disease is
pauci-bacillary. Numerous scoring systems have been developed
but no validated scoring system exists.32 Because there is no cor-
relate of protection, TB vaccine efﬁcacy trials depend on clinical
disease endpoints.33 In a trial setting, it is imperative that endpoints
are as speciﬁc as possible to ensure that efﬁcacymeasures are a true
reﬂection of vaccine beneﬁt. An attempt to determine an interna-
tionally agreed endpoint for TB vaccine efﬁcacy trials in infants
reached only a partial consensus.24 Using our experience from
previous trials23,26 we developed a hierarchical, three tiered end-
point which we felt would be most suited to an infant TB vaccine
efﬁcacy trial (Table 1). While Graham et al.34 have published con-
sensus endpoints for TB diagnostics studies, it was agreed that such
endpoints may not be suitable for infant TB vaccine trials due to
active case ﬁnding and a younger study population. Active case
ﬁnding truncates further disease progression because of early iso-
niazid preventive therapy (IPT) and TB treatment; children younger
than 2 years are at risk for rapid progression to military/meningitic
TB in the absence of a classical respiratory symptomatic phase seen
in older children. Our endpoints contain elements which are
pathognomonic of TB e bacteriological conﬁrmation by culture
and/or nucleic acid ampliﬁcation test (GeneXpert, Cepheid) and
clinical syndromes for TB meningitis, opthalmic TB and typical
histological ﬁndings. However, these forms of TB are less common.
A triad of features more commonly used to diagnose TB in children
e evidence of latent TB infection, a chest X-ray compatible with TB
and symptoms of TB e were added to the endpoint deﬁnition. All
three elements were required to conﬁrm a diagnosis of TB to ensure
that the endpoint would be as speciﬁc as possible. Endpoint 2 al-
lows a slightly less rigorous deﬁnition of TB disease than Endpoint
1, based upon the triad of TB exposure/infection, radiographic
features and symptoms. Although the symptom and radiological
criteria are identical, the Endpoint 2 criteria for TB exposure/
infection are widened to include children with a lower TST
threshold (10mm) and children living in a household with a known
smear positive sputum TB patient.
4.2. Operational activities
The study was more staff intensive than initially anticipated.
Staff salaries comprise a large proportion of the costs of efﬁcacy
trials, but it would be false economy to reduce the stafﬁng com-
plement but then have to lengthen the trial to meet targets. On the
other hand, we have shown that ﬂexibility with regards to staff
roles and responsibilities, changing the recruitment window, cen-
trifugation of blood specimens prior to transport and good coun-
selling with phlebotomy procedures are improvements that add
minimally to trial costs but beneﬁt recruitment progress.
The principal investigator is held accountable for informed
consent. However, according to International Conference on Har-
monisation (ICH) and South African GCP guidelines,35,36 he/she
may delegate this to a suitably qualiﬁed person. Certain sponsors
nevertheless require a medically qualiﬁed investigator to conduct
consent. In developing countries, this is not always feasible, par-
ticularly when enrolling large numbers of participants. We have
shown that non-medical staff when well trained with competency
checks and frequent monitoring, were able to conduct informed
consent which met international and local standards.
“Normal” ranges used by diagnostic laboratories around the
world are often based onWestern populations, as was the casewith
normal platelet ranges in our study. Other African research sites
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results in 1) the possible exclusion of healthy participants and 2)
abnormal laboratory results being classiﬁed as adverse events in
enrolled participants with subsequent repeat blood draws until
‘resolution’. Clinical trial data or speciﬁcally designed surveys of
local healthy populations should be used to deﬁne normal ranges
that are appropriate and relevant to the study setting and popu-
lation for use in both patient care and clinical trials.
Stockouts of EPI vaccines do occur commonly in developing
country settings and contingency plans need to be in place should
trials require their prior administration as an inclusion criterion.
National vaccination campaigns will affect trials where admin-
istration of other vaccines is an exclusion criterion. Unless solu-
tions are found to these factors, a costly pause in enrolment may
occur. Excellent communication channels between SATVI and
the local health services at all levels served to minimise the impact
of these potentially detrimental episodes during our enrolment
phase.5. Conclusion
We describe the ﬁrst proof-of-concept trial of a new TB vaccine
in infants since BCG. The rationale for speciﬁc efﬁcacy endpoints is
provided. We have described the challenges encountered by a site
experienced in clinical trials with investigational medicinal prod-
ucts and the need for constant monitoring, evaluation and adap-
tation. The solutions we implemented will be of value in the
planning of efﬁcacy trials of other TB vaccine candidates.Acknowledgments
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